Bone health management in patients with breast cancer: current standards and emerging strategies.

[1]  F. Cardoso,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. , 2011, The Lancet. Oncology.

[3]  J. Carter,et al.  Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. V. Von Roenn,et al.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Cameron,et al.  Abstract S4-5: Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04) , 2010 .

[6]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Neven,et al.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  B. van Hout,et al.  Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Ellis,et al.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.

[10]  R E Coleman,et al.  The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer , 2010, British Journal of Cancer.

[11]  J. Mackey,et al.  Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Holen,et al.  Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction , 2010, British Journal of Cancer.

[13]  K. Toulis,et al.  Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab , 2010, Osteoporosis International.

[14]  S. Cremers,et al.  Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. , 2010, The Journal of clinical endocrinology and metabolism.

[15]  E. Perez,et al.  The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up. , 2009 .

[16]  M. Fitch,et al.  Bone metastases from advanced cancers: clinical implications and treatment options. , 2009, Clinical journal of oncology nursing.

[17]  D. Goulis,et al.  Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[18]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  R. Greil,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[20]  M. Nissen,et al.  Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. , 2009, The journal of supportive oncology.

[21]  E. Perez,et al.  Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. , 2009, Clinical breast cancer.

[22]  Arnold Knijn,et al.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. , 2009, European journal of cancer.

[23]  Muhammad Salim,et al.  Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Fehm,et al.  Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. , 2009 .

[25]  F. Schuetz,et al.  Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  R. Chlebowski,et al.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Cremers,et al.  Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Dodwell,et al.  Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[29]  C. Blomqvist,et al.  Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. , 2008, The Lancet. Oncology.

[31]  I. Holen,et al.  Exploring the anti-tumour activity of bisphosphonates in early breast cancer. , 2008, Cancer treatment reviews.

[32]  M. Aapro,et al.  Practical guidance for the management of aromatase inhibitor-associated bone loss. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  F. Saad,et al.  Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid , 2008, Cancer.

[34]  S. Perera,et al.  Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Moasser,et al.  Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow , 2008 .

[36]  D. Gold,et al.  Compliance and persistence with osteoporosis therapies , 2007, Current rheumatology reports.

[37]  E. McCloskey,et al.  Cost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer Patients , 2008, The Journal of international medical research.

[38]  M. Beckmann,et al.  Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Saad,et al.  Pathologic fractures correlate with reduced survival in patients with malignant bone disease , 2007, Cancer.

[40]  R. Cook,et al.  Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. , 2007, The oncologist.

[41]  P. Delmas,et al.  Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. , 2007, Bone.

[42]  J. Reginster,et al.  Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club , 2007, Osteoporosis International.

[43]  J. Cramer,et al.  Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills* , 2007, Current medical research and opinion.

[44]  L. Costa,et al.  P141 Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate , 2007 .

[45]  E. Perez,et al.  Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Gnant,et al.  Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[48]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[50]  M. Ettinger,et al.  Medication persistence with weekly versus daily doses of orally administered bisphosphonates. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[51]  E. Perez,et al.  Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  E. Brankin,et al.  Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study , 2006, International journal of clinical practice.

[53]  J. Hay,et al.  Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  H. Gothe,et al.  Higher persistency with i.v. bisphosphonates in patients with bone metastasis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  D. Pendharkar,et al.  Loading dose ibandronate in rapid pain management of metastatic bone disease (MBD). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Milella,et al.  Benefit of taxanes as adjuvant chemotherapy for early breast cancer , 2006, Cancer.

[57]  K. Kahler,et al.  Adherence and Persistence Associated with the Pharmacologic Treatment of Osteoporosis in a Managed Care Setting , 2006, Southern medical journal.

[58]  T. Powles,et al.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] , 2006, Breast Cancer Research.

[59]  J. Reginster.  Adherence and persistence: impact on outcomes and health care resources. , 2006, Bone.

[60]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[61]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  M. Neary,et al.  Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. , 2005, Clinical therapeutics.

[63]  M. Stockler,et al.  Bisphosphonates for breast cancer. , 2005, The Cochrane database of systematic reviews.

[64]  A. Shamseddine,et al.  Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. , 2005, The Journal of clinical endocrinology and metabolism.

[65]  R. Stupp,et al.  Proven bioequivalence of blood exposure between vinorelbine 80 mg/m2 oral and 30 mg/m2 IV doses in cancer patients , 2005 .

[66]  Y. Ohashi,et al.  Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  D. Cameron,et al.  Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration , 2005, British Journal of Cancer.

[68]  E. McCloskey,et al.  Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK , 2005, Current medical research and opinion.

[69]  N. Laperriere,et al.  Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group , 2006 .

[70]  A. Howell,et al.  P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases , 2005 .

[71]  H. Kroger,et al.  Smoking and fracture risk: a meta-analysis , 2005, Osteoporosis International.

[72]  I. Holen,et al.  Sequence‐ and schedule‐dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells , 2005, International journal of cancer.

[73]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[74]  O Johnell,et al.  A family history of fracture and fracture risk: a meta-analysis. , 2004, Bone.

[75]  R. Bell,et al.  Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer , 2004, Pain.

[76]  R. Coleman.  Bisphosphonates: clinical experience. , 2004, The oncologist.

[77]  J. Body,et al.  Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  J. Abrahm.  Assessment and treatment of patients with malignant spinal cord compression. , 2004, The journal of supportive oncology.

[79]  O Johnell,et al.  A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.

[80]  C. Blomqvist,et al.  Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients , 2004, Acta oncologica.

[81]  Olof Johnell,et al.  A Meta‐Analysis of Prior Corticosteroid Use and Fracture Risk , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[82]  D. Tripathy,et al.  Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies , 2004, British Journal of Cancer.

[83]  F Berrino,et al.  EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[86]  W. Sauerbrei,et al.  Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) , 2003, Osteoporosis International.

[87]  M. Lichinitser,et al.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  R. Cook,et al.  Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical Endpoints , 2002, American journal of clinical oncology.

[89]  Z. Tran,et al.  Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[90]  P. Wiffen,et al.  Bisphosphonates for the relief of pain secondary to bone metastases. , 2002, The Cochrane database of systematic reviews.

[91]  O. Johnell,et al.  Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds , 2001, Osteoporosis International.

[92]  J. Manola,et al.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  P. Delmas,et al.  Markers of bone turnover in bone metastases , 2000, Cancer.

[94]  A. Lipton.  Bisphosphonates and breast carcinoma , 2000, Cancer.

[95]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[96]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[97]  T. Spector,et al.  A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.

[98]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[99]  J. Compston,et al.  Prevention and Management of Osteoporosis , 1997, Drugs.

[100]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[101]  K. Jaeggi,et al.  Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[102]  S. T. Harris,et al.  Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. , 2009, Medscape journal of medicine.

[103]  R. Carlson,et al.  The decline in breast cancer incidence: Real or imaginary? , 2009, Current oncology reports.

[104]  J. Cuzick,et al.  OC11. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) , 2008 .

[105]  G. Hortobagyi,et al.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[106]  A. Howell,et al.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.

[107]  A. Heidenreich,et al.  Ibandronate in the treatment of prostate cancer associated painful osseous metastases , 2002, Prostate Cancer and Prostatic Diseases.

[108]  C. Blomqvist,et al.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  C. Blomqvist,et al.  Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. , 1997, British Journal of Cancer.

[110]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.